Chimeric Receptors with 4-1BB Stimulatory Signaling Domain (SJ-03-0018A)

Technology Name
(St. Jude Reference #)
Chimeric Receptors with 4-1BB Stimulatory Signaling Domain (SJ-03-0018A)
Description A targeted immunotherapy that utilizes a patented anti-CD19 CAR to genetically modify human immune cells (US 8,399,645). This CAR stimulates immune cells to destroy the most common forms of adult and childhood B cell cancers including acute lymphoblastic leukemia (ALL), B-cell chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma (NHL). Each year approximately 71,650 people in the United States are diagnosed with these diseases.
Keywords anti-CD19 Chimeric Antigen Receptor, CAR, leukemia therapy
Granted Patents or Published Applications U.S. Patent No. 8,399,645
Related Scientific References A press release issued by St. Jude is available here:
Licensing Opportunities We are currently entertaining offers to license this technology from a number of companies. If your company would like to be included in this process, please contact us as soon as possible for more information.


Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.


Last update: August 2013